e-learning
resources
ERJ
2014
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Vallath Sabari, Hynds Robert E., Succony Laura, Janes Sam M., Giangreco Adam
Source:
Eur Respir J 2014; 44: 513-522
Journal Issue:
August
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vallath Sabari, Hynds Robert E., Succony Laura, Janes Sam M., Giangreco Adam. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J 2014; 44: 513-522
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease
Source: Eur Respir J, 56 (2) 1902320; 10.1183/13993003.02320-2019
Year: 2020
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma
Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
Year: 2019
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury
Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021
Year: 2021
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020
Year: 2020
The promise of mTOR signaling as a therapeutic target for IPF
Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
Year: 2020
Failure of EGFR TKI treatment: mechanisms and current strategies?
Source: ERS Research Seminar
Year: 2015
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Targeting the mTOR signaling pathway to inhibit lung cell senescence in chronic obstructive pulmonary disease (COPD)
Source: ERS Lung Science Conference 2017
Year: 2017
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019
Year: 2019
Common therapeutic approaches in IPF and lung cancer
Source: Research Seminar 2015
Year: 2015
Interstitial lung disease: new challenges and evolving phenotypes
Source: Eur Respir Rev 2009; 19: 91-93
Year: 2010
Targeting the arginase pathway: potential developments as new avenues for treatment
Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma?
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept